Plain-English translation of NCT07193810 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage clinical trial testing a new medication called for people with three serious autoimmune diseases: systemic lupus erythematosus (lupus), idiopathic inflammatory myopathies (muscle inflammation), or systemic sclerosis (hardening of the skin and organs). The trial is designed to see if the medication is safe and whether it helps people whose disease has not improved or has gotten worse despite standard treatments.
Many people with these autoimmune diseases do not respond well to currently available treatments and continue to suffer from active disease. This trial exists to explore whether this new medication could offer a helpful option for people in that difficult situation.
You likely qualify if…
You likely don't qualify if…
You would receive doses of as part of a study that examines how your body handles the medication, whether it is safe, and whether it helps reduce your disease activity. The study involves multiple visits where you'll have blood tests, physical exams, and assessments of how your symptoms change over time. This is a small, early-stage study enrolling only about 6 participants total, and your doctors will carefully monitor you for any side effects.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
CytoCares Inc
Enrollment target
~6 participants
Started
September 2025
Primary completion
September 2027
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
CEO
CytoCares Inc
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.